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Abstract
In a previous study using state-of-the-art proteomic techniques, we identiﬁed colligin 2
(HSP47) as a glioma blood vessel-speciﬁc protein. In the present study we precisely local-
ized the expression of colligin 2 in the blood vessels of diffusely inﬁltrating gliomas and
relate the expression to the distinct cellular components of the vessels by using multiple
immunolabeling and confocal microscopy. We grouped the glioma blood vessels into mor-
phological categories ranging from normal looking capillaries to vessels with hypertrophic
and sclerotic changes. The expression patterns of various markers of endothelial and peri-
cytic differentiation were correlated with the position of the cells in the vessels and the
expression of colligin 2. We found that colligin 2 is expressed in all categories of glioma
blood vessels in cells with endothelial and pericytic lineage. Expression of colligin 2 was
also found in cells scattered around blood vessels and in few glial ﬁbrillary acidic protein-
positive cells within the blood vessels. There is overlap in the expression of colligin 2 and
the collagens type I and IV for which colligin 2 is a chaperon.We conclude that colligin 2 is
expressed in all cellular components of glioma blood vessels and may serve as a general
marker for active angiogenesis.
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INTRODUCTION
Gliomas are among the neoplasms with the highest degree of vas-
cularization (19). These neoplasms contain increased numbers of
blood vessels relative to normal brain tissue, and the vessel walls
are variably thickened because of proliferation of their cellular
constituents (5). Along with glial tumor progression, normal-
looking blood vessels gradually hypertrophy into glomeruloid
structures with multiple lumina ultimately degenerating into
end-stage vessels with sclerotic walls and obliterated lumina (12).
Many vessels become prone to thrombosis and recanalization
of organized thrombi is a frequently observed phenomenon. The
newly formed blood vessels are leaky because of the defective and
aberrant basal membrane formation (24). It has long been appreci-
atedthattumorgrowthandprogressionaredependentonangiogen-
esis, but the elucidation of the molecular mechanisms that trigger
the formation of new blood vessels is still in its early stage (3).
Although many aspects of the angiogenic switch, that is, the transi-
tion of dormant pre-existing blood vessels into an actively sprout-
ingvasculaturearenotunravelledyet,avarietyofangiogenicregu-
lators have been detected (37) and some have already been tested
for the development of anti-angiogenic therapies (25). Besides the
therapeutic approach aiming at destroying glioma vasculature,
attempts to normalize the structure and function of the newly
formed and dysfunctional blood vessels are also undertaken for
reaching better penetration of chemotherapeutics and optimize
conditions for effective radiation therapy (8, 15). In order to
manipulate the cerebral microcirculation, knowledge of the inter-
play of the cells involved and of the underlying molecular mecha-
nisms is required (31).
The cells in blood vessel walls are characterized either by their
position relative to the vascular lumina and/or by their immunohis-
tochemical proﬁles. In normal blood vessels, endothelial cells are
considered to line the lumina and express CD31 (4), CD34 (27),
Von Willebrand factor (36) and more. Pericytes (also indicated as
smooth muscle cells or mural cells) form an incomplete layer
around the endothelial cells (32). CD105 is a marker for activated
endothelialcellstakingpartinneoangiogenesisnotonlyingliomas
but also in other tumors (13, 20, 23). Most available data on the
cells involved in neoangiogenesis concern endothelial cells and
factors regulating their proliferation (11, 16). In recent studies the
importance of pericytes and their interaction with endothelial cells
for blood vessel formation, stabilization and function was high-
lighted (28, 33). There are indications of the existence of various
subtypes of pericytes in various organs with different functions
and locations in the vessels (2, 34). Immunohistochemical marker
proﬁles for pericytes are diverse and vary between organs and
developmental stages (2). Because of this diversity, no general
pan-pericytic marker is known (3). A well-known marker for peri-
cytes in cerebral vasculature is a-smooth muscle actin (aSMA)
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(7) and has been instrumental in proving that pericytic precursor
cellsarerecruitedtositeswherevesselgrowthandrepairareoccur-
ring (6). Recently, endosialin was found to be strongly upregulated
in pericytic cells in the developing human brain (33) and glioma
(28). Its expression is closely associated with other perivascular
cells(28).Othermarkersusedtoidentifypericytesincludeplatelet-
derived growth factor receptor beta (PDGFR-b) (33), CD13 and
desmin (35), but none is speciﬁc for these cells.
In a previous study using state-of-the-art proteomics techniques,
colligin 2 was identiﬁed as a protein that is expressed in glioma
neovasculature but not in normal brain vasculature (21). In addi-
tion, we found that expression of colligin 2 is not limited to glioma
vasculature, but is also seen in vasculature of non-glial tumors.
Further, its expression is found in non-neoplastic tissues, but only
undercircumstancesofactiveangiogenesislikewoundhealingand
recanalization of thrombi. Colligin 2 protein (also known as col-
lagen binding stress protein; HSP 47) is localized in the endoplas-
mic reticulum and speciﬁcally binds to collagen type I, collagen
type IV and gelatin (14). It assists in the formation of the rigid
triple-helical structures of collagen type I (22) and contributes to
the maturation of collagen type IV (18). Collagen is the major
component of the basement membrane and a crucial element of the
blood–brain barrier (BBB) (1, 9, 30).The aim of the present study
was to precisely localize the expression of colligin 2 in the blood
vessel walls of gliomas and associate the expression to the speciﬁc
cellular components of the vessel walls in order to obtain indica-
tions as to the role of this protein in glioma angiogenesis. To this
end, in addition to conventional microscopy of adjacent slides,
confocal microscopy was used because of the superior levels of
resolution and creating three-dimensional representations.
MATERIALS AND METHODS
Patients and tumor samples
Twenty glioblastoma (GBM) samples were taken from the ﬁles of
theDepartmentofPathology,ErasmusMC,Rotterdam.Inaddition,
seven samples of autopsy brains of patients without brain tumors
were used as controls. Post-mortem times of the control cases were
8 h or less. For immunohistochemical staining, parafﬁn embedded
andfresh-frozensampleswereuseddependingonthespeciﬁcations
of the antibodies and type of staining. For application of confocal
microscopy, fresh-frozen samples were used. The number of
samples,clinicaldataandtumortypesaresummarizedinTable 1.
Immunohistochemistry
Single-staining procedures
Twelve biopsy samples of GBMs and ﬁve autopsy control samples
were used.The samples were collected in a consecutive way. From
each parafﬁn embedded sample, adjacent slides of 5 mm sections
were stained with various antibodies. Because NG2 and CD105
antibodies do not work on parafﬁn embedded tissues, these and the
Table 1. Clinical data for the patient that had been used in this study.
Abbreviations: ARDS = adult respiratory distress syndrome; AVM =
arteriovenous malformation; F = frontal; GBM = glioblastoma; LE = left;
P = parietal; RI = right; SAB = subarachnoidal hemorrhage; T = temporal.
High-grade diffusely inﬁltrating glioma
Glioma
samples
Sex Age
(years)
Tumor
site
Diagnosis
T1 Female 30 Ri F GBM
T2 Female 30 Ri F GBM
T3 Female 54 Le F-P GBM
T4 Female 58 Le F-P GBM
T5 Female 63 Le F GBM
T6 Male 36 Le F GBM
T7 Male 44 Multifocal GBM
T8 Male 46 Le T GBM
T9 Male 47 Le T GBM
T10 Male 47 Ri T-P GBM
T11 Male 48 Le F GBM
T12 Male 51 Ri F GBM
T13 Male 55 Ri F GBM
T14 Male 56 Le T-P GBM
T15 Male 57 Le T GBM
T16 Male 57 Ri F GBM
T17 Male 57 Le T GBM
T18 Male 62 Le T GBM
T19 Male 62 Le T GBM
T20 Male 68 Le F GBM
Controls
Normal
samples
Sex Age
(years)
Location Diagnosis
S1 Female 39 Ri F SAB
S2 Female 48 Ri F SAB
S3 Female 60 Ri F Pneumonia
S4 Female 76 Ri F Pneumonia
S5 Male 31 Ri F AVM
S6 Male 34 Ri F Hemorrhage brain stem
S7 Male 70 Ri F ARDS
Table 2. Antibodies used in this study.
Name Dilution Commercial source
Monoclonal colligin 2 1:500 Stressgen, Michigan, USA
Polyclonal colligin 2 1:100 MBL international, Woburn, Canada
CD31 1:40 Dako, Glostrup, Denmark
CD34 1:30 Dako, Glostrup, Denmark
CD105 1:2000 Dako, Glostrup, Denmark
NG2 1:100 ZYMED laboratories, California, USA
Endosialin 1:500 Prof. Isacke, Institute of Cancer
Research, London, UK
aSMA 1:40 Biogenex, California, USA
Collagen I 1:100 Abcam, Cambridge, UK
Collagen IV 1:25 Dako, Glostrup, Denmark
Mib-1 (Ki-67) 1:10 Dako, Glostrup, Denmark
GFAP 1:100 Dako, Glostrup, Denmark
Goat-anti-mouse-CY3 1:100 BioLegend, California, USA
Biotin-horse-anti-mouse 1:200 Vector, Peterborough, UK
Avidin-FITC 1:50 Jackson Immunoresearch,
Pennsylvania, USA
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histochemical staining was performed following the manufac-
turer’s instructions (alkaline phosphatase technique).The antibod-
ies and their speciﬁcations are summarized in Table 2. Brieﬂy, the
parafﬁn sections were mounted onto poly-L-lysin-coated slides,
deparafﬁnized in xylene for 15 minutes and rehydrated through
graded alcohol and washed with water. Frozen sections were ﬁxed
in acetone for 15 minutes and then air-dried. The sections were
washed with phosphate-buffer saline (PBS) and incubated with the
antibody for 30 minutes.After washing the sections with PBS, the
corresponding antigen was added and incubated 30 minutes at
room temperature. New Fuchsin alkaline phosphatase substrate
solution was freshly prepared and the sections were incubated for
about 30 minutes. Afterwards, the sections were washed with tap
water, counterstained and coverslipped with permanent mounting
medium.
Double staining procedures
Double immunolabelings were performed combining colligin 2
antibody with the various markers for endothelial cells and peri-
cytes.Ten frozen biopsy samples of GBMs were used for confocal
laser microscopy. Adjacent slides of 5-mm sections were mounted
onto non-coated microscope slides, ﬁxed in acetone for 15 minutes
and then air-dried. Sections were incubated with colligin 2 poly-
clonal antibody for 30 minutes, washed and incubated again with
Cy3-conjugated goat anti-rabbit for 30 minutes. After washing,
sections were incubated with the second monoclonal antibody for
30 minutes followed by 30 minutes of labeling with biotin–horse–
anti-mouse antibody. Detection was performed by ﬂuorescein
isothiocyanate (FITC)-conjugated avidin antibody. Nuclei were
counterstained with 4′,6-diamidino-2-phenylindole (DAPI) in a
vector sheet (1:1000) and slides were covered and examined with
the confocal laser microscope. For all antibodies the staining was
always performed single on each sample also, to control for the
accuracy of the staining and speciﬁcity of the antibodies used. For
each antibody, negative controls including the secondary antibod-
ies only were obtained for both single- and double-stained slides.
The speciﬁcations of the antibodies are summarized in Table 2.
Confocal laser-scanning microscopy
Using the confocal microscope allowed the staining and samples
with two different antibodies. In addition, the resolution of the
confocal microscope and its ability to produce three-dimensional
optical images enabled speciﬁc targeting the cellular components
ofgliomabloodvesselsinamoreaccurateandreliableway.Confo-
cal images were obtained using a confocal laser-scanning micro-
scope (LSM510; Carl Zeiss Microimaging Inc., Jena, Germany)
equipped with a Plan-Neoﬂuar 40¥/1.3 NA oil objective (Carl
Zeiss Microimaging Inc.).A diode laser was used for excitation of
DAPI at 405 nm, an argon laser for FITC at 488 nm and a HeNe-
laser for Cy3 at 543 nm. For DAPI an emission bandpassﬁlter of
420–480 nm was used, for FITC a bandpassﬁlter of 500–530 nm
and for CY3 a longpassﬁlter of 560 nm.The signals were recorded
sequentially (multitrack option) to avoid interference and stored in
separate channels.
Table 3. Immunostaining of blood vessels in a
normal brain.
Layers in normal cerebral blood
vessels
CD31 CD34 CD105 NG2 Endosialin aSMA Colligin 2
Endothelial cells (lumina-lining) ++- - - - -
Pericytes (abluminal lining) --- - - + /--
Table 4. Immunostaining of blood vessels in glioma. Abbreviation: ND = not determined.
Glioma blood vessel subtype Layers CD31 CD34 CD105 NG2 Endosialin aSMA Colligin 2
Small, normal-looking vessels Single +++ + + + +
Layered/organized hypertrophied vessels Inner +++ - + - +
Middle --- + - + +
Outer --+ + + + +
Un-layered/ disorganized hypertrophied vessels Inner +++ - - - +
Middle --+ + + + +
Outer --+ + + + +
Glomeruloid vessels Inner +++ + + + +
Other layers --+ + + + +
Recanalized vessels Inner ++ND ND +/-+ /-+ /-
Other layer --ND ND +/-+ /-+ /-
Table 5. Confocal laser microscopy of glioma blood vessels.
Endothelial cells Pericytes
Positive Negative Positive Negative
CD31 NG2 NG2 CD31
CD34 aSMA Endosialin CD34
CD105 aSMA CD105 +/-
Colligin 2 Colligin 2
Endosialin +/-
+/- shows varies results depending on the type of blood vessel.
Expression of colligin 2 in glioma Mustafa et al
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normal brain. A–D. CD31, CD34 and collagen
IV are all expressed in capillaries. aSMA is
variably expressed (panels A, B,D: ¥40; panel
C: ¥20). E–J. CD31, CD34, aSMA, collagen IV
are expressed in small vessels in normal brain;
endosialin and colligin 2 are not expressed
(E,F–H,J: ¥40; I: ¥20).
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Immunohistochemistry
Normal brain
The endothelial cells of small and medium-sized vessels in the
samples of a normal brain showed immunopositivity for CD31 and
CD34 but not for aSMA (Table 3). The mural cells were variably
positiveforaSMA.Noneofthecellsofthebloodvesselsinnormal
brain were positive for CD105, NG2, endosialin or colligin 2
(Figure 1 and Table 3).
Glioma
The vessels encountered in the glioma samples were divided in:
small vessels including capillaries, which did not show morpho-
logical changes; vessels with hypertrophied walls (either with
organized layering as in normal larger blood vessels or with disor-
ganized, haphazardly arranged cellular components); vessels with
glomeruloid appearance and vessels with signs of recanalization.
The lumina-lining cells of capillaries in glioma were invariably
positive for CD31, CD34 and CD105 (Figure 2; Table 4). In addi-
tion, there was immunopositivity for aSMA, endosialin and NG2.
Expression of colligin 2 was found in all small blood vessels
Figure 2. Expression of the various markers in
capillaries and small vessels in glioma. All
capillaries and small vessels are invariably
positive for the markers indicated (panels
A,C,E: ¥40; B,D,F–H: ¥20).
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layering, the endothelium expressed CD31 and CD34 while the
intermediate and the external layers expressed aSMA and NG2
(Table 4). The inner (endothelial) and outer layer of these vessels
expressed endosialin and CD105 while cells in between these two
layers remained negative for these two markers. Colligin 2 was
expressed in all cell layers of the hypertrophied blood vessels
(Figure 3).Inthehypertrophiedvesselswithdisorganizedarranged
cellular components, the internal diameter of the lumen appeared
irregular while the external diameter of the vessel wall varied per
segment of the vessel.The endothelium stained positive for CD31,
CD34 and CD105 but not for aSMA, NG2 or endosialin (Table 4).
The abluminal cells of these vessels stained positive for CD105,
aSMA, NG2 and endosialin. Colligin 2 was expressed in all layers
Figure 3. Expression of the various markers in
layered hypertrophic blood vessels in glioma.
CD31 and CD34 are expressed in the
endothelial layer. CD105 and endosialin are
expressed in the endothelium and the external
layer. aSMA, NG2 and collagen IV are
expressed in the intermediate and external
layers, not in the endothelium. Colligin 2 is
expressed in all layers of the vessels (panels
A–F: ¥40). G–K. Confocal images of layered
hypertrophic blood vessels in glioma for the
expression of CD105. Double immunolabeling
for CD105/colligin 2. The endothelial cells and
the external cells express both CD105 and
colligin 2, while the intermediate cells express
colligin 2 only (arrows) (panel H: green =
CD105; panel I: red = colligin 2; panel J:
blue = DAPI; panel K: merged picture).
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cells are haphazardly arranged around multiple small lumina. The
lumina-lining cells of the glomeruloid blood vessels were positive
for CD31, CD34 and CD105. The cells in the abluminal position
stained positive for endosialin, NG2, and aSMA (Table 4). The
expression of colligin 2 was positive in all cellular components of
these blood vessels (Figure 5).The lumina-lining cells of the larger
recanalized vessels were positive for CD31, CD34 and CD105
(Table 4). The other cells stained positive for aSMA, endosialin
and colligin 2. Remarkably, a minority of cells in the recanalized
thrombi remained negative for all markers used (Figure 6).
Confocal laser microscopy
Thehighresolutionoftheconfocalmicroscopeenablestodetailthe
expression of the various markers at the level of individual cells. In
all distinguished types of glioma blood vessels, the lumina-lining
endothelial cells were positive for CD31 and CD34, while none
of the other cellular components were positive for these markers
(Figure 7). CD105, a marker for activated endothelial cells,
was expressed by the endothelial cells in all different types of
blood vessels in the glioma samples (Figure 8). The percentage of
endothelial cells that expressed colligin 2 varied between the blood
vessels in the same sample and ranged between high-, and hardly
any expression. In some endothelial cells, expression levels of
colligin 2 was the same as that of CD31 or CD34, while other cells
showedaverylowlevelofexpression.
The pericytic markers NG2, endosialin and aSMA were com-
binedwithcolligin2.Inalltypesofbloodvessels,NG2andaSMA
were exclusively found in the layers around the endothelium and
these cells also expressed colligin 2. Endosialin was expressed
around the endothelium as well, but a low percentage of the endot-
helial cells of the various blood vessel subtypes also expressed
this protein (Figure 9). Interestingly, scattered individual colligin
2-positive cells were present around all blood vessel subtypes.
These colligin 2-expressing cells lacked expression of any of the
endothelial or pericytic cell markers.
Becausecolligin2isthechaperonforthecollagentypesIandIV,
we included these proteins in our investigations.There appeared to
be an overlap in expression of colligin 2 and collagen type I and IV.
However, not all colligin 2-positive cells showed expression
of collagen. For instance, some cells in the glomeruloid and small
blood vessels exclusively expressed colligin 2 (Figure 10).
The endothelial cells remained negative for collagens I and IV.
Figure 4. Expression of the various markers in
hypertrophic vessels without layered structure.
CD31 is exclusively expressed in the
endothelial layer; CD105 and colligin 2 are
expressed in all layers. SM-A, NG2 and
endosialin are present in all layers except the
endothelial layer (all panels ¥40).
Expression of colligin 2 in glioma Mustafa et al
56 Brain Pathology 20 (2010) 50–65
© 2008 The Authors; Journal Compilation © 2008 International Society of NeuropathologyNoticeably, the individual colligin 2-expressing cells found around
the blood vessels never expressed the two collagens (Figure 10).
The proliferation-related marker Mib-1 was combined with colli-
gin2andco-expressionwasseeninsomeendothelialcellsofsmall
and hypertrophied vessels. In the glomeruloid vessels Mib-1
expression was seen in both colligin 2 positive and negative cells
(Figure 11). The glial ﬁbrillary acidic protein (GFAP)-positive
astrocytes residing outside the blood vessels remained negative for
colligin 2, but a very low percentage of these cells participating in
the glioma blood vessel formation were found to co-express colli-
gin 2 (Figure 12).
DISCUSSION
In our previous work, we discovered that colligin 2 is expressed in
glioma vasculature but not in the blood vessels of normal brain
(21). The aim of the present study was to investigate which subset
of vessels and which cellular components of the glioma neovascu-
lature express colligin 2. The results show that colligin 2 was
expressed at various stages of glioma blood vessels: in new vascu-
lar sprouts; in hypertrophied vessels; in glomeruloid vessels; and
alsoinend-stageandthrombosedvesselsinwhichrecanalizationis
takingplace.Moreover,theexpressionofcolligin2wasdiscovered
Figure 5. Expression of the various markers in
glomeruloid blood vessels in glioma. CD31,
CD34 and CD105 are expressed in the
endothelial layer. SM-A, Ng2, endosialin,
colligin 2 and collagen IV are expressed in all
components of the vessels (panels A–C,E–H:
¥40; D: ¥20).
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any morphological change. Because colligin 2 was expressed in
active angiogenesis but was not seen in blood vessels of normal
brains it may be considered as an early marker for angiogenesis in
gliomavasculaturethatremainspresentthroughoutthelifecycleof
the vessels.
At the level of single cells, colligin 2 is present in the lumina-
lining endothelial cells showing co-expression of the endothelial
markers CD31, CD34 and CD105 (Table 5).As CD105 is a marker
for activated endothelial cells, colligin 2 seems to be linked with
endothelial activation and active angiogenesis. Colligin 2 is also
expressedbypericyticormuralcellscharacterizedbyimmunoposi-
tivity for aSMA, NG2 and endosialin (Table 5). In normal human
development,ithasbeenshownthatendothelialcellsaredrivenand
guided by migrating pericytes during organization of the growing
vessel walls (33). The immunohistochemical proﬁles that are the
basis for the distinction of the various cells in the glioma blood
vessels like endothelial cells or pericytes are less consistent than
suggested in the literature so far.The lumina-lining cells of normal
brain vasculature invariably express CD31 and CD34 while the
expressionofthepericyticmarkeraSMAvariesbetweenvesselsof
comparablesizes(Table 3).AlphaSMAisexpressedinalltypesand
sizesofbloodvesselsofgliomaalthoughitsexpressionislimitedto
only few blood vessels in the normal brain samples. The markers
NG2,endosialinandcolligin2wereallexclusivelyfoundinglioma
blood vessels but never in the blood vessels in the normal brain
samples. As reported in the literature, endosialin is expressed in
pericytes of glioma tissue (28). The present results conﬁrm the
speciﬁcity of endosialin for glioma vasculature and that endosialin
is present in pericytes, but also show that endosialin is present in
someendothelialcells(Figure 9).Toalesserextent,NG2showedan
overlap in expression with endothelial markers and appeared to be
morespeciﬁcforpericyticcells.Theexclusiveexpressionofcolligin
2andendosialininmorphologicallynormalbloodvesselsinglioma
is illustrative of a shift in protein expression patterns prior to mor-
phological changes. Interestingly, using confocal microscopy we
foundasubsetofcellsinbraintissuecloseto,butnotincontactwith,
glioma blood vessels to express colligin 2. These cells did not
expressanyoftheendothelial/pericyticmarkersusedinthisstudy.It
maywellbethatthesecellsaremigratingvascularprecursorcellson
theirwaytomergeintothevesselwalls,or,alternatively,becomede
novo blood vessels. This is compatible with colligin 2 expression
reﬂecting an early stage of vascular development. Further explora-
tionastothelineageandoriginofthesecellsisindicated.
Figure 6. Expression of the various markers in
recanalized vessels in glioma. CD31 and CD34
are expressed in the endothelial layer. SM-A,
endosialin, colligin 2 are expressed by the
surrounding cells. Collagen IV is expressed
throughout the vessel wall (all panels ¥20).
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expression of colligin 2 in the endothelial cells. A–E. Double immunola-
beling for CD31/colligin 2 in a small blood vessel. Some CD31 expressing
cells are positive for colligin 2 (arrow). Some cells around the blood
vessels exclusively express colligin 2 (asterisk) [panel B: green = CD31;
panel C: red = colligin 2; panel D: blue = 4′,6-diamidino-2-phenylindole
(DAPI); panel E: merged picture]. F–J. Double immunolabeling for CD34/
colligin 2 in a hypertrophied blood vessel. A complete overlap in expres-
sion of CD34 and colligin 2 in endothelial cells (arrow). Colligin 2 is also
expressed by CD34-negative pericytes (panel G: green = CD34; panel H:
red = colligin 2; panel I: blue = DAPI; panel J: merged image).
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a collagen-binding stress protein localized in the endoplasmic
reticulum (14). In the normal situation the expression of HSP47
precedes that of collagen, and in various cell types and tissues the
co-expression of the proteins is present (26). The expression of
HSP47 and several types of collagen is induced under pathological
conditions (29). Colligin 2 is essential for the maturation of col-
lagen by assisting in the correct folding and supporting the trans-
portation of collagen to the basal membrane.The absence of colli-
gin 2 causes defective maturation of the microﬁbrills of collagen
type I and IV and impaired formation of the basal membrane (18).
Colligin 2 knockout mice did not survive beyond 11.5 days post-
fertilization and displayed abnormally orientated epithelial tissues
and ruptured blood vessels (22). Inactivation of the expression of
colligin 2 seriously affects the function of the basal membrane of
blood vessels (17). Our results conﬁrm the anticipated overlap in
expression of colligin 2 with collagen types I and IV in the glioma
blood vessels, corroborating the signiﬁcance of colligin 2 for the
formation of the basal membrane.The fact that expression of colli-
gin 2 precedes the expression of collagen may well explain absent
co-expression in some of the vascular cells examined in this study.
Resistance of brain tumors to therapy may in part be caused by
the abnormal functioning of tumor vasculature caused by patho-
logical changes of the BBB. Normally, astrocytic end-feet and
basal membrane substance of the cerebral blood vessels both con-
tribute to the BBB. The majority of blood vessels in glioma loses
contact with astrocytic end-feet and loses normal anatomy and
function. Disruption of the BBB was noticed in our investigations.
In glioma vasculature, glial cells may participate in glioma angio-
genesis (so-called “mosaic vessels”) (10), but normal formation of
the end-feet for a normal BBB function is absent. In this study, by
double labeling colligin2 and GFAP, we excluded the expression of
colligin 2 by astrocytes in glioma tissue, but we encountered scat-
tered astrocytes in the glioma blood vessels that expressed GFAP
and colligin 2.This ﬁnding indicates that some astrocytes or astro-
cytic tumor cells that contribute to glioma blood vessels switch
their protein expression repertoire to take part in angiogenesis.
GFAP-/colligin 2-positive cells were never found in glioma tissue
and they were very rarely present in the glioma blood vessels.
Nevertheless, this ﬁnding is important when considering vascular
cell populations for therapeutic intervention. The properties
and functions of the glial cells in the mosaic vessels need further
investigation.
In conclusion, we conﬁrm that colligin 2 is expressed in glioma
vasculature and we found that its expression is by the distinct cell
compartments of the tumor vasculature, whether they are activated
endothelialcellsorcellswithimmunoproﬁlesofpericytes.Inaddi-
tion, scattered cells without the immunophenotype of endothelial
or pericytic cells were also immunopositive for colligin 2, as were
some GFAP-positive cells in some of the vessel walls. Because
colligin 2 is detected in a spectrum from morphologically normal
to severely disﬁgured glioma blood vessels, it potentially may
become in use as a marker for active angiogenesis or serve as a link
to targeted anti-angiogenic strategies.
Figure 8. Confocal images of glioma blood vessels for the expression of
colligin 2 by activated (CD105-positive) endothelial cells. A–E. Double
immunolabeling for CD105/colligin 2 in hypertrophied blood vessel.
CD105 and colligin 2 are expressed by endothelial cells while the cells
around the endothelium express only colligin 2 (arrows) (panel B:
green = CD105; panel C: red = colligin 2; panel D: blue = 4′,6-diamidino-
2-phenylindole; panel E: merged picture).
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colligin 2 by the surrounding cells/pericytes. A–E. Double immunolabel-
ing for NG2/colligin 2 in hypertrophied blood vessel. Cells expressing
NG2 show expression of colligin 2 (arrow). NG2 is not expressed by the
endothelial cells. Some cells around the blood vessels exclusively
express colligin 2 (asterix) (panel B: green = NG2; panel C: red = colligin
2; panel D: blue = DAPI; panel E: merged picture). F–J. Double immuno-
labeling for endosialin/colligin 2 in hypertrophied blood vessel. Cells
expressing endosialin are positive for colligin 2 as well (arrow). Some
cells around the blood vessels show exclusive expression of colligin 2
(asterix) [panel G: green = endosialin; panel H: red = colligin 2; panel I:
blue = 4′,6-diamidino-2-phenylindole (DAPI); panel J: merged picture].
K–O. Double immunolabeling for SM-A/colligin 2 in small blood vessel.
Expression of endosialin and colligin 2 in the same cells of the vessel
wall. Exclusive expression of colligin 2 in cells around the blood vessels
(asterisk) (panel L: green = endosialin; panel M: red = colligin 2; panel N:
blue = DAPI; panel O: merged picture).
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© 2008 The Authors; Journal Compilation © 2008 International Society of NeuropathologyFigure 10. Confocal images of glioma blood vessels for the expression
of colligin 2 and collagen type I and IV. A–E. Double immunolabeling for
collagen type I and colligin 2 in hypertrophied blood vessel. The endothe-
lial cells express colligin 2 only (stars), while the surrounding cells
express both colligin 2 and collagen I [panel B: green = collagen I; panel
C: red = colligin 2; panel D: blue = 4′,6-diamidino-2-phenylindole (DAPI);
panel E: merged picture]. F–J. Double immunolabeling for collagen type
IV and colligin 2 in a small blood vessel. Double expression of collagen IV
and colligin 2 in the cells around the endothelium, while endothelial cells
only express colligin 2. Exclusive expression of colligin 2 in cells around
the blood vessels (stars) (panel G: green = collagen IV; panel H:
red = colligin 2; panel I: blue = DAPI; panel J: merged picture).
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© 2008 The Authors; Journal Compilation © 2008 International Society of NeuropathologyFigure 11. Confocal images of glioma blood vessels for the expression
of colligin 2 in Mib-1 positive cells. A–E. Double immunolabeling for
Mib-1/colligin 2 in a small blood vessel. A fraction of colligin 2 positive
endothelial cells are Mib-1 positive (arrows) [panel B: green = collagen I;
panel C: red = colligin 2; panel D: blue = 4′,6-diamidino-2-phenylindole
(DAPI); panel E: merged picture]. F–J. Double immunolabeling for
Mib-1/colligin 2 in glomeruloid vessels in glioma. Some Mib-1 positive
endothelium-surrounding cells express colligin 2 (arrows) while others
do not (stars) (panel G: green = Mib-1; panel H: red = colligin 2; panel I:
blue = DAPI; panel J: merged picture).
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